We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
Read MoreHide Full Article
Viatris Inc. (VTRS - Free Report) delivered fourth-quarter 2024 adjusted earnings of 54 cents per share, which missed the Zacks Consensus Estimate of 57 cents. The company recorded adjusted earnings of 62 cents per share in the year-ago quarter.
Total revenues were $3.53 billion, down 8.5% year over year. The top line included product sales and other revenues. Revenues missed the Zacks Consensus Estimate of $3.6 billion.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Shares are trading down in response to the disappointing results. VTRS’ share price has dropped 4.8% year to date compared with the industry’s 16.6% decline.
All growth rates mentioned below are on a year-over-year basis.
Image Source: Zacks Investment Research
VTRS’ Q4 Sales in Detail
Sales totaled $3.5 billion, down 8%. Sales were up 1% on a divestiture-adjusted operational basis compared to the prior-year results.
The company reports under four segments — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ) and Greater China.
Sales from Developed Markets amounted to $2.15 billion, down 7%. The reported figure missed the Zacks Consensus Estimate of $2.17 billion.
Sales from Emerging Markets totaled $513.2 million, down 17%. The figure missed the Zacks Consensus Estimate of $539 million.
JANZ generated sales of $334.5 million, down 10%. Sales missed the Zacks Consensus Estimate of $366 million.
Sales from Greater China totaled $521.8 million, up 1%. The figure missed the Zacks Consensus Estimate of $553 million.
Based on product category, revenues from Brands decreased 10% to $2.1 billion. On a divestiture-adjusted operational basis, sales were flat, reflecting the expansion of the portfolio in Emerging Markets and JANZ, and strong growth in Greater China.
Among Brands, Lipitor sales totaled $355.9 million, down from $379.6 million in the year-ago quarter. Norvasc sales decreased to $166.2 million from $171.8 million a year ago. Lyrica sales declined to $127 million from $133 million.
Yupelri sales totaled $66.6 million, up from $60.5 million in the year-ago quarter.
Generics, which includes diversified product forms such as extended-release oral solids, injectables, transdermals, and topicals and complex generics, posted revenues of $1.3 billion, down 5%. On an operational change basis, sales were up 2%.
Viatris generated $85 million in new generic product revenues. It expects to generate $450-$550 million in new product revenues in 2025.
Adjusted gross margin was 56.3%, down from 57.5% reported in the year-ago quarter.
VTRS 2024 Results
Revenues of $14.7 billion were down 4.4% from 2023 and missed the Zacks Consensus Estimate of $14.8 million. Adjusted EPS of $2.65 was down from $2.93 in 2023 and missed the Zacks Consensus Estimate of $2.68.
Total revenues are projected to be in the band of $13.5-$14 billion. Adjusted earnings per share are expected to be in the range of $2.12-$2.26.
Other Updates From VTRS
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, VTRS received a warning letter and import alert from the FDA in December 2024.
The import alert affects 11 actively distributed products, including lenalidomide and everolimus. However, the regulatory body made exceptions for four products based on shortage concerns.
While these products continue to be shipped from the Indore facility to markets outside the United States, VTRS currently anticipates some impact in other markets. Due to this, VTRS estimates 2025 revenues to be negatively impacted by approximately $500 million.
Our Take on VTRS’ Q4 Performance
The company reported lower-than-expected fourth-quarter results, wherein the top and bottom lines missed their respective estimates. The guidance for 2025 was disappointing as well.
In the past 30 days, Gilead Sciences’ earnings estimates for 2025 have improved from $7.56 to $7.81 per share. During the same timeframe, EPS for 2026 has improved to $8.17 from $7.82.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 earnings per share have increased from $4.01 to $4.19. Estimates for 2026 earnings per share have decreased from $5.21 to $5.20 during the same timeframe. BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
In the past 30 days, the estimate for Amicus Therapeutics’ 2025 earnings per share has remained constant at 43 cents. The estimate for 2026 earnings per share has moved down from 72 cents to 71 cents. FOLD’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 45.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
Viatris Inc. (VTRS - Free Report) delivered fourth-quarter 2024 adjusted earnings of 54 cents per share, which missed the Zacks Consensus Estimate of 57 cents. The company recorded adjusted earnings of 62 cents per share in the year-ago quarter.
Total revenues were $3.53 billion, down 8.5% year over year. The top line included product sales and other revenues. Revenues missed the Zacks Consensus Estimate of $3.6 billion.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Shares are trading down in response to the disappointing results. VTRS’ share price has dropped 4.8% year to date compared with the industry’s 16.6% decline.
All growth rates mentioned below are on a year-over-year basis.
Image Source: Zacks Investment Research
VTRS’ Q4 Sales in Detail
Sales totaled $3.5 billion, down 8%. Sales were up 1% on a divestiture-adjusted operational basis compared to the prior-year results.
The company reports under four segments — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ) and Greater China.
Sales from Developed Markets amounted to $2.15 billion, down 7%. The reported figure missed the Zacks Consensus Estimate of $2.17 billion.
Sales from Emerging Markets totaled $513.2 million, down 17%. The figure missed the Zacks Consensus Estimate of $539 million.
JANZ generated sales of $334.5 million, down 10%. Sales missed the Zacks Consensus Estimate of $366 million.
Sales from Greater China totaled $521.8 million, up 1%. The figure missed the Zacks Consensus Estimate of $553 million.
Based on product category, revenues from Brands decreased 10% to $2.1 billion. On a divestiture-adjusted operational basis, sales were flat, reflecting the expansion of the portfolio in Emerging Markets and JANZ, and strong growth in Greater China.
Among Brands, Lipitor sales totaled $355.9 million, down from $379.6 million in the year-ago quarter. Norvasc sales decreased to $166.2 million from $171.8 million a year ago. Lyrica sales declined to $127 million from $133 million.
Yupelri sales totaled $66.6 million, up from $60.5 million in the year-ago quarter.
Generics, which includes diversified product forms such as extended-release oral solids, injectables, transdermals, and topicals and complex generics, posted revenues of $1.3 billion, down 5%. On an operational change basis, sales were up 2%.
Viatris generated $85 million in new generic product revenues. It expects to generate $450-$550 million in new product revenues in 2025.
Adjusted gross margin was 56.3%, down from 57.5% reported in the year-ago quarter.
VTRS 2024 Results
Revenues of $14.7 billion were down 4.4% from 2023 and missed the Zacks Consensus Estimate of $14.8 million. Adjusted EPS of $2.65 was down from $2.93 in 2023 and missed the Zacks Consensus Estimate of $2.68.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
VTRS 2025 Guidance
Total revenues are projected to be in the band of $13.5-$14 billion. Adjusted earnings per share are expected to be in the range of $2.12-$2.26.
Other Updates From VTRS
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, VTRS received a warning letter and import alert from the FDA in December 2024.
The import alert affects 11 actively distributed products, including lenalidomide and everolimus. However, the regulatory body made exceptions for four products based on shortage concerns.
While these products continue to be shipped from the Indore facility to markets outside the United States, VTRS currently anticipates some impact in other markets. Due to this, VTRS estimates 2025 revenues to be negatively impacted by approximately $500 million.
Our Take on VTRS’ Q4 Performance
The company reported lower-than-expected fourth-quarter results, wherein the top and bottom lines missed their respective estimates. The guidance for 2025 was disappointing as well.
Zacks Rank and Stocks to Consider
Viatris currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the sector are Gilead Sciences (GILD - Free Report) , BioMarin Pharmaceutical (BMRN - Free Report) and Amicus Therapeutics (FOLD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, Gilead Sciences’ earnings estimates for 2025 have improved from $7.56 to $7.81 per share. During the same timeframe, EPS for 2026 has improved to $8.17 from $7.82.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 earnings per share have increased from $4.01 to $4.19. Estimates for 2026 earnings per share have decreased from $5.21 to $5.20 during the same timeframe. BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
In the past 30 days, the estimate for Amicus Therapeutics’ 2025 earnings per share has remained constant at 43 cents. The estimate for 2026 earnings per share has moved down from 72 cents to 71 cents. FOLD’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 45.42%.